(Amlodipine + fimasartan potassium) is under clinical development by Dongkook Pharmaceutical and currently in Phase I for Idiopathic (Essential) Hypertension. According to GlobalData, Phase I drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Amlodipine + fimasartan potassium) LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Amlodipine + fimasartan potassium) overview

DKF-407 is a fixed dose combination of amlodipine, fimasartan potassium. It is under development for the treatment of idiopathic (essential) hypertension. Amlodipine acts by targeting calcium channel and fimasartan acts by targeting angiotensin II type 1 (AT1) receptor. It is administered by oral route.

Dongkook Pharmaceutical overview

Dongkook Pharmaceutical (Dongkook) is a pharmaceutical company. It develops, manufactures and distributes pharmaceutical products, healthcare products and medical devices. Its offers products that include generic drugs, quasi-drugs, prescription-based drugs, medical devices and active pharmaceutical ingredients. It provides products under the brands Insadol Plus, Madecassol, Feramine Q, Sencia, Pansidil, Chisen, Karitopoten, Oramedi and others. It operates a factory located in Jincheon-gun, South Korea. Dongkook is headquartered in Gangnam-gu, Seoul, South Korea.

For a complete picture of (Amlodipine + fimasartan potassium)’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.